Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 697-704

  Sinapis, Christos I ^a   Routsias, John G ^a   Sinapis, Angelos I ^a   Sinapis, Dimitrios I ^a   Agrogiannis, George D ^a   Pantopoulou, Alkistis ^a   Theocharis, Stamatis E ^a   Baltatzis, Stefanos ^a   Patsouris, Efstratios ^a   Perrea, Despoina ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bevacizumab; Intravitreal; Pharmacokinetics; Rabbits

Indexed keywords

BEVACIZUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; ENUCLEATION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RABBIT; TIME TO MAXIMUM PLASMA CONCENTRATION; VITREOUS BODY;

EID: 79958797675     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S19555     Document Type: Article

References (27)

1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
2. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125l-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol. 1999;27:536-544.
3. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal administration of bevacizumab (Avastin). Retina. 2006;26:262-269.
4. Eduardo Dib, Mauricio Maia, Ieda Maria Longo-Maugeri, et al. Sub-retinal Bevacizumab Detection after Intravitreous Injection in Rabbits. Invest Ophthalmol Vis Sci. 2008;49:1097-1100.
5. Michels S, Rosenfeld PJ, Puliafto CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047.
6. Ladewig MS, Ziemssen F, Jaissle G, et al. Intravitreal bevacizumab for neovascular age-related macular degeneration. Ophthalmologe. 2006; 103:463-470.
7. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999-1005.
8. Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860-1867.
9. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmolog y. 2006;113:1695-1705.
10. Jaissle GB, Ziemssen F, Petermeier K, et al. Bevacizumab for treatment of macular edema secondary to retinal vein occlusion. Ophthalmologe. 2006;103:471-475.
11. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007;27:1004-1012.
12. Rosenfeld PJ, Moshfeghi AA, Puliafto CA. Optical coherence tomography fndings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging. 2005;36:331-335.
13. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ. Pharmacokinet-ics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007;114: 855-859.
14. Nomoto H, Shiraga F, Kuno N, et al. Pharmacokinetics of bevacizumab after topical, sub conjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci. 2009;50:4807-4813.
15. Qi Zhu, Focke Ziemssen, Sigrid Henke-Fahle, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology. 2008;115: 1750-1755.
16. Yanyali A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol. 2007;144:124-126.
17. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevaci-zumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004; 7:335-345.
18. Iyer MN, He F, Wensel TG, et al. Clearance of intravitreal moxifoxacin. Invest Ophthalmol Vis Sci. 2006; 47:317-319.
19. Fauser S, Kalbacher H, Alteheld N, et al. Pharmacokinetics and safety of intravitreally delivered etanercept. Graefes Arch Clin Exp Ophthalmol. 2004;242:582-586.
20. Scholes GN, O' Brien WJ, Abrams G W, Kubicek MF. Clearance of tri-amcinolone from vitreous. Arch Ophthalmol. 1985;103:1567-1569.
21. Krohne T, Eter N, Holz F, Meyer C. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146:508-512.
22. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25:556-560.
23. Beer PM, Bakri SJ, Singh RJ, et al. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003;110:681-686.
24. European Medicines Agency (EMEA). Avastin (bevacizumab): scientifc discussion. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/avastin/17199204en6.pdf. Accessed September 28, 2007.
25. European Medicines Agency (EMEA). Lucentis (ranibizumab): scientifc discussion. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/lucentis/H-715-EN6.pdf. Accessed September 28, 2007.
26. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Phar-macokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179-2182.
27. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharma-cokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726-733.